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Abstract
Objective—To assess the efficacy and safety of a 24-week course of abatacept in the treatment 
of active lupus nephritis. An additional exploratory objective was to assess the potential of 
abatacept to induce ‘clinical tolerance’, defined as sustained clinical quiescence of lupus nephritis 
after discontinuation of immunosuppressive therapy.
Methods—Patients (n=134) with active lupus nephritis were studied in a randomized, double-
blind phase II add-on trial in which they received either abatacept or placebo in conjunction with 
the Euro-Lupus regimen of low-dose cyclophosphamide followed by azathioprine. The primary 
efficacy outcome was the frequency of complete response (CR) at week 24. Thereafter, patients 
who met either complete or partial response criteria continued blinded treatment through week 52. 
During this phase of the study, subjects in the abatacept treatment group who had achieved CR 
status at week 24 discontinued immunosuppressive therapy other than prednisone (10 mg/d).
Results—There were no statistically significant differences between groups with respect to the 
primary outcome or any of the secondary outcomes, including measures of safety. Thirty-three 
percent of subjects in the treatment group and 31% of subjects in the control group achieved CR 
status at week 24. Fifty percent of subjects in the treatment group who met CR criteria and 
therefore discontinued immunosuppressive therapy at week 24 maintained their CR status through 
week 52.
Conclusion—The addition of abatacept to a regimen of cyclophosphamide followed by 
azathioprine did not improve the outcome of lupus nephritis at either 24 or 52 weeks. No 
worrisome safety signals were encountered.
There are no consistently safe and effective treatments for lupus nephritis. Induction therapy 
for active nephritis typically consists of moderate-to-high dose glucocorticoids (GC) 
combined with an additional potent immunosuppressive drug, followed by maintenance 
therapy involving long-term sustained immune suppression [1]. Despite this aggressive 
approach to treatment, many patients continue with active nephritis and/or recurrent flares, 
and all patients are exposed to the risks of therapy, including the potential for fatal 
complications.
For several decades, the standard of care for active lupus nephritis consisted of monthly 
intravenous pulses of cyclophosphamide (CTX) for at least six months, with a target of 
achieving modest depression of circulating leukocyte counts between doses. This approach 
had emerged from a relatively small trial that compared high-dose GC alone with several 
alternative regimens consisting of GC in combination with other immunosuppressive agents 
[2]. Progression to renal failure occurred most often among patients who received GC alone. 
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Although the trial did not distinguish convincingly among the various combination 
regimens, the community adopted pulse CTX as the preferred approach. In recent years, two 
other approaches have been compared to high-dose pulse CTX and appear to have 
equivalent efficacy. One approach is based on the Euro-Lupus Nephritis Trial (ELNT). It 
utilizes a shorter and less intense regimen of CTX followed by maintenance therapy with 
azathioprine (AZA) [3, 4]. The other approach utilizes mycophenolate mofetil (MMF) 
instead of pulse CTX [5–8]. There is reason to believe that these regimens may be safer than 
high-dose pulse CTX.
Against this background, there has been great hope that the advent of targeted biologic 
therapies would lead to breakthroughs in the treatment of lupus nephritis. Thus far, however, 
these hopes have not been realized [1, 9]. CTLA4Ig is among the biologic interventions that 
have generated great interest. The rationale for testing CTLA4Ig in lupus nephritis is very 
strong. CTLA4Ig blocks binding of antigen-presenting cells to CD28 on T cells, thereby 
inhibiting activation of primary T-dependent immune responses [10]. CTLA4Ig may also 
have direct inhibitory effects on the B cell lineage, as CD28 is expressed on plasma cells; 
whether CD28 engagement mediates positive or negative regulation remains an area of 
controversy [11–13]. In murine models for SLE, CTLA4Ig acts synergistically with CTX to 
arrest lupus nephritis [14, 15]. In humans, CTLA4Ig (abatacept) is effective in the treatment 
of rheumatoid arthritis [16, 17]. Moreover, a post-hoc analysis of a large trial of abatacept 
(ABA) in people with lupus nephritis strongly suggested clinical benefit [18]. Finally, a 
recent study of patients with focal segmental glomerulosclerosis showed that treatment with 
ABA induced disease remission, apparently by binding to CD80 on renal podocytes [19]. 
Taken together, these observations provide a strong foundation for postulating that ABA 
may be effective in people with lupus nephritis.
PATIENTS AND METHODS
Study design and treatment protocol
The ACCESS trial was a 1:1 randomized, double-blind, controlled phase II multicenter trial 
of ABA vs placebo on a background of treatment with GC plus CTX followed by AZA in 
patients with active lupus nephritis. The trial consisted of two phases. In the first phase, 
patients with active lupus nephritis were randomized to receive monthly infusions of either 
placebo or ABA. Subjects in both groups also received six biweekly pulses of CTX followed 
by oral AZA based on the ELNT regimen [3] as well as a tapering regimen of oral GC. The 
primary outcome measure was the proportion of subjects who achieved a complete response 
(CR) at week 24.
Treatment was initiated with monthly infusions of either placebo or ABA at doses that were 
adjusted for body weight according to the ABA dose that is recommended for rheumatoid 
arthritis (<60 kg, 500 mg; 60–100 kg, 750 mg; >100 kg, 1 gram). All patients received six 
intravenous pulses of 500 mg of CTX at two-week intervals followed by oral AZA at 2 
mg/kg/d based on the ELNT regimen. This control regimen differed slightly from the 
original ELNT regimen with respect to the approach to GC treatment. Unlike the ELNT 
trial, the ACCESS trial did not employ an initial intravenous pulse of GC, but rather left that 
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decision to the site investigator’s discretion. Oral GC treatment was begun at 60 mg/d for 
two weeks in all subjects, followed by a prescribed taper to 10 mg/d over the next 10 weeks.
The second phase of the trial (weeks 24–52) was exploratory and was intended to generate 
preliminary data regarding the potential of ABA to restore self-tolerance, defined as 
sustained quiescence of nephritis off immunosuppressive therapy. In this phase, patients 
who met CR criteria on ABA at week 24 then discontinued immunosuppression with ABA 
and AZA at week 28 and continued only on prednisone 10 mg/d. Patients who had achieved 
only a partial response on ABA continued therapy with monthly infusions of ABA and daily 
oral AZA. In the control group, patients who had achieved either a complete or partial 
response continued AZA. Patients who were non-responders at week 24 discontinued the 
trial at that point. Institutional review boards at all sites approved the study design, and all 
subjects provided written informed consent.
Study subjects
Eligible subjects were 16 years of age or older. They fulfilled the American College of 
Rheumatology (ACR) criteria for SLE, and they had a positive antinuclear antibody (ANA) 
and/or a positive anti-double-stranded DNA antibody test at study entry. All subjects had 
active lupus nephritis, defined by: (a) kidney biopsy documentation within the last 12 
months of International Society of Nephrology/Renal Pathology Society (ISN/RPS) 
proliferative nephritis (class III or class IV, with or without features of class V); and (b) 
urine protein-to-creatinine ratio (UPCR) >1. Overall, 137 subjects were enrolled, of whom 
134 met entry criteria and comprised the intent-to-treat population for the efficacy analysis. 
Study subjects came from 19 sites in the United States and two sites in Mexico. Enrollment 
began in November 2008 and concluded in June 2012.
Study endpoints and assessments
The primary efficacy endpoint was the proportion of subjects who achieved a complete renal 
response (CR) at week 24. CR was defined as all of the following: (i) UPCR <0.5 based on a 
24-hour urine collection; (ii) serum creatinine ≤1.2 mg/dL or ≤125% of baseline; and (iii) 
adherence to the prednisone taper to 10 mg/d by week 12. Prospectively defined secondary 
efficacy endpoints included: (i) the proportion of subjects who achieved a partial response 
(PR) at week 24, defined by the same criteria as the CR definition except that the UPCR 
component of the PR definition required only a 50% improvement from baseline rather than 
a decline to <0.5; (ii) the proportion of subjects who met the UPCR and GC criteria for CR 
at week 24; (iii) the proportion of subjects who met the UPCR and GC criteria for PR at 
week 24; (iv) the proportion of subjects who met either CR or PR criteria at week 52; (v) the 
proportion of subjects who achieved CR status at week 24 and who maintained that response 
to week 52; (vi) time to CR or PR; and (vii) lupus disease activity as reflected by reduction 
of anti-dsDNA antibodies, resolution of hypocomplementemia (C3 or C4), patient global 
assessment, the 36-Item Short-Form Health Survey (SF36) score [20], and the British Isles 
Lupus Assessment Group (BILAG)-2004 score [21]. Secondary efficacy endpoints also 
included frequency of lupus flares, either renal or non-renal. For subjects who had achieved 
CR status at week 12 or any time thereafter, a renal flare was defined as recurrence of 
proteinuria >1 gm/24 hours. For all others, a renal flare was defined as either of the 
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following: (i) serum creatinine at least 25% higher than baseline or above the upper limit of 
normal, plus proteinuria at least 75% of baseline; or (ii) doubling of UPCR compared with 
the lowest previous value. A non-renal flare was defined by the BILAG-2004 guidelines as 
any new ‘A’ finding in a nonrenal organ system. Adverse events (AEs) were graded 
according to the National Cancer Institute Common Terminology Criteria for Adverse 
Events (version 3.0).
Power/sample size
Using data from the ELNT [3, 4], the statistical analysis plan was based on the assumption 
that the proportion of CR outcomes at week 24 in the control group would be 20%. Our goal 
was to detect a 30% increase in the CR rate in the ABA group (50% compared to 20%). 
Subjects dropping out of the study prior to week 24 were handled as clinical response 
failures for the primary analysis. As such, after adjusting for an expected 10% dropout rate 
equally distributed to the two groups, this difference corresponds to an expectation of 45% 
CR in the ABA group and 18% CR in the control group. To detect this 27% difference at 
90% power using a two-sided Fisher’s exact test at the 0.05 level of significance, a sample 
size of 67 subjects per group was required.
RESULTS
Study population
Sixty-eight subjects were randomized to the control group, and 66 subjects were randomized 
to the ABA treatment group (Figure 1). Baseline characteristics were well-matched between 
treatment groups (Table 1). Approximately 90% of subjects were women. The mean age at 
entry was 32 years. The study population was racially and ethnically diverse, including 39% 
African American subjects and 40% Hispanic or Mestizo subjects. Thirty-four percent of the 
subjects had ISN/RPS LN class III with or without features of class V, and 66% had class IV 
with or without features of class V. Forty-six percent of subjects in the control group and 
41% of subjects in the treatment group entered the trial with UPCR>3. Seventy-one percent 
of subjects in each group had duration of nephritis <1 year. At the time of study entry, 60% 
of subjects were receiving an antimalarial drug and 73% of subjects were receiving either an 
angiotensin-converting-enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB). 
The use of these agents was comparable between the two treatment groups.
Primary Outcome Measure
There was no significant difference in the CR rate at week 24 between the ABA and control 
groups (Figure 2a) (Fisher’s exact test). CRs occurred in 21/68 (31%) of control subjects and 
22/66 (33%) of ABA-treated subjects.
Secondary Efficacy Outcome Measures
The frequency of total responses (complete or partial) was identical in the two groups at 
59% (Figure 2b). There also were no statistically significant differences in any of the other 
pre-specified secondary outcome measures (Table 2), including: (i) the proportion of 
subjects who met the proteinuria and prednisone requirements for CR or PR; (ii) the 
proportion of subjects who had a 75% reduction in anti-dsDNA antibodies; (iii) the 
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proportion of subjects with negative anti-dsDNA; (iv) resolution of hypocomplementemia as 
measured by C3 or C4 levels; (v) time to CR or PR; (vi) patient global assessment; (vii) 
SF-36 physical and mental scores; (viii) BILAG-2004 score, or (ix) frequency of flares. The 
mean UPCR at week 24 was 1.1 ± 1.2 in the control group compared to 1.1 ± 1.3 in the 
ABA group (p=ns). The CR rate was lowest among Black subjects in the control group 
(16% vs 40% among non-Black control subjects), but no such difference was observed in 
the ABA group (33% CR in both Black and non-Black subjects) nor were any of the 
differences among racial and ethnic groups statistically significant. CR and PR rates were 
not significantly different when comparing subjects with recent onset of nephritis (<1 year) 
to subjects with a longer history of nephritis (≥1 year) (data not shown).
Safety
There were no clinically or statistically significant differences between groups at week 24 in 
total adverse events, lupus-related adverse events, serious adverse events, serious infectious 
adverse events, opportunistic infections, or withdrawals due to adverse events (Table 3). 
There was one death, due to sepsis, in the control group.
Outcomes at Week 52
Forty subjects from the control group and thirty-nine subjects from the ABA group 
continued per protocol beyond the primary endpoint at week 24. Their outcomes are shown 
in Table 4. According to the protocol, the 22 subjects in the ABA group who met CR criteria 
at week 24 discontinued ABA and AZA at week 28 and continued on prednisone alone 10 
mg/d thereafter. Eleven of these subjects (50%) maintained CR status through week 52, 
compared to 13/21 (62%) subjects in the control group who maintained CR status while 
continuing AZA through week 52 (p=ns). One subject in each group deteriorated from CR at 
week 24 to PR at week 52. Two subjects in the ABA group and four subjects in the control 
group either withdrew due to a renal flare or failed to meet either CR or PR criteria at week 
52. One patient in the ABA group withdrew due to a non-renal flare, and several subjects in 
each group withdrew for reasons unrelated to lupus or study treatment. Overall, 13 subjects 
in the control group withdrew from the trial due to active nephritis, compared to 5 subjects 
in the ABA group (Fig. 1).
All subjects who were classified as PR at week 24 continued their immunosuppressive 
treatment during weeks 24–52. Again, there were no significant differences between groups. 
The most common outcome in both groups was to improve from PR status at week 24 to CR 
status at week 52 (Table 4).
There were no statistically significant differences in any of the secondary outcome measures 
at week 52 (not shown). With regard to safety between weeks 24 and 52, there were ten 
SAEs (5 in each group), no discontinuations due to infection, and no deaths.
DISCUSSION
This trial did not demonstrate any benefit for ABA when added to a regimen consisting of 
low-dose pulse CTX followed by AZA in patients with lupus nephritis. This finding 
suggests that ABA may not be effective in lupus nephritis. However, there are alternative 
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explanations that might account for the outcome. This trial explored only one dose regimen, 
which was based on the dose of ABA that is approved for the treatment of rheumatoid 
arthritis. It is possible, therefore, that a higher dose might be required for lupus nephritis. 
Background therapy may be important. In this trial, we chose to use CTX as the foundation 
for the background regimen, based on studies in murine lupus suggesting potential synergy 
between ABA and CTX [14, 15]. By using a low-dose approach to CTX therapy, we may 
have used too little to achieve a synergistic benefit. A post-hoc analysis of a prior trial of 
ABA in lupus nephritis suggested possible benefit on a background of MMF [18], so 
perhaps a combination with MMF would be more effective. Finally, this add-on trial 
demonstrated that ABA does not provide additional benefit when superimposed on 
background therapy initiated with high-dose GC followed by CTX and AZA. However, it 
does not establish whether ABA might demonstrate comparable efficacy in a head-to-head 
trial design. In that context, it is even possible that the background GC therapy or the 
multiple doses of CTX in this trial interfered with the mechanism of action of ABA. It may 
be noteworthy in that respect that the preclinical mouse studies that contributed to the 
foundation for this trial did not employ GC at all. Although the alternative explanations for 
the trial results are all plausible, it would be a daunting task to put them to the test.
A unique aspect of this trial was the opportunity it provided to acquire preliminary data on 
the impact of discontinuing immunosuppressive therapy in patients who achieve CR status 
within 24 weeks. This opportunity resulted from three factors. First, there is a biologic 
rationale for postulating that CTLA4Ig might induce tolerance among autoreactive T cells 
[10, 22]. Second, studies in mice indicate that the beneficial effect of CTLA4Ig on murine 
lupus nephritis persists even after treatment is discontinued [23]. Third, this trial was 
supported by the Immune Tolerance Network, which has a mission to evaluate therapies that 
have the potential to induce clinical tolerance, defined as quiescence of autoimmune disease 
in the absence of ongoing immunosuppressive therapy. This goal is particularly important in 
lupus, where it is unknown whether the risks of long-term immunosuppression exceed the 
risks of discontinuing therapy in patients who achieve a complete response. There is little 
information in the literature to address this issue. One trial demonstrated that continued 
immunosuppression with pulse methylprednisolone plus CTX was preferable to reliance on 
pulse methylprednisolone alone as maintenance therapy, but that result was based on an 
examination of the overall study population and did not focus on the minority of subjects 
who had achieved complete responses [24]. Similarly, retrospective analyses of longitudinal 
cohorts have demonstrated the benefit of maintenance therapy for the entire cohort, but have 
not provided data about the risk:benefit ratio specifically for subjects without evidence of 
active disease [25]. A recent report described successful withdrawal of immunosuppressive 
therapy from lupus nephritis patients in remission, but in that report the duration of 
treatment for lupus nephritis varied between 2.5 and 10 years prior to gradual tapering and 
eventual discontinuation of therapy (26). In the ACCESS trial, we discontinued 
immunosuppressive therapy in 22 subjects in the ABA treatment group who met CR criteria 
at week 24, because those were the subjects in whom the scientific rationale for 
discontinuing therapy was strongest. Eleven of those subjects maintained their CR status 
through week 52. The 50% success rate at maintaining CR in this group was similar to the 
62% (13/21) success rate among subjects in the control group maintained on AZA who met 
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CR criteria at week 24. These exploratory findings cannot be interpreted to imply that ABA 
contributed to the sustained quiescence, but they raise the possibility that, once a complete 
response is achieved, it may be possible to discontinue immunosuppression, monitor patients 
closely, and avoid the risks of ongoing immunosuppression. There was no difference 
between the groups in the number of subjects who lost their renal response or had a non-
renal flare between weeks 24 and 52 (3/22 complete responders who discontinued 
immunosuppressive therapy compared to 4/21 complete responders who continued AZA 
maintenance therapy). The number of subjects in this exploratory analysis is small, but the 
results suggest that further study is warranted to determine whether maintenance therapy 
should be continued after establishment of CR.
The ACCESS trial provided an important opportunity to explore the effectiveness of the 
Euro-Lupus treatment strategy in a racially and ethnically diverse North American 
population. Previous studies of this regimen strongly suggested that a less aggressive 
approach to pulse CTX might be as effective as, and safer than, the more intense CTX 
regimen that has long been the standard of care [3, 4]. However, those studies involved 
primarily Northern European lupus patients, of whom most were White patients with 
newonset rather than refractory nephritis. Due to the nature of the study population, there 
has been a reluctance to generalize those results to other populations, especially Black and 
Hispanic populations who tend to have more severe and refractory disease [27–32]. By 
succeeding in recruiting a racially and ethnically diverse population of lupus patients that 
more closely resembles the overall demographics of lupus, we have been able to show that 
the response rates for the Euro-Lupus regimen in this population closely match, or slightly 
exceed, the response rates for high-dose CTX or MMF reported from other trials [6, 9], 
although the efficacy of this regimen in Blacks warrants further study.
There have now been two trials of ABA in patients with lupus nephritis. Neither trial 
achieved its primary outcome goal. The prior trial employed a control regimen of MMF 
rather than CTX/AZA [18]. Although that trial failed to meet its primary endpoint, a post-
hoc analysis suggested that there may have been efficacy that wasn’t captured by the 
prospectively defined endpoint [18]. Therefore, a second large, multicenter international trial 
of ABA on a background of MMF is currently underway (NCT01714817). The results of 
that trial will provide additional data to determine whether ABA will have a role in the 
treatment of lupus nephritis.
Acknowledgments
This research was performed as a project of the Immune Tolerance Network (NIH contract N01-AI-15416; protocol 
number ITN034AI), an international research consortium headquartered at the University of California, San 
Francisco. The Immune Tolerance Network is funded by the National Institute of Allergy and Infectious Diseases. 
Abatacept was provided by Bristol-Myers Squibb (BMS).
The principal investigators of the ACCESS Trial, Betty Diamond and David Wofsy, have received consulting fees 
from BMS in the past, but did not receive any remuneration from BMS for the conduct or analysis of this trial. 
Their participation in this trial was supported in part by their institutions, the Feinstein Institute for Medical 
Research at Northshore-Long Island Jewish Health System and the Russell/Engleman Rheumatology Research 
Center at the University of California San Francisco.
et al. Page 8










1. Hahn BH, et al. American College of Rheumatology guidelines for screening, treatment, and 
management of lupus nephritis. Arthritis Care Res (Hoboken). 2012; 64(6):797–808. [PubMed: 
22556106] 
2. Austin HA 3rd, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. 
N Engl J Med. 1986; 314(10):614–619. [PubMed: 3511372] 
3. Houssiau FA, et al. Immunosuppressive therapy in lupus nephritis: the Euro- Lupus Nephritis Trial, 
a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 
2002; 46(8):2121–2131. [PubMed: 12209517] 
4. Houssiau FA, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-
dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010; 69(1):61–64. [PubMed: 
19155235] 
5. Ginzler EM, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N 
Engl J Med. 2005; 353(21):2219–2228. [PubMed: 16306519] 
6. Appel GB, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus 
nephritis. J Am Soc Nephrol. 2009; 20(5):1103–1112. [PubMed: 19369404] 
7. Dooley MA, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N 
Engl J Med. 2011; 365(20):1886–1895. [PubMed: 22087680] 
8. Chan TM, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus 
nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000; 343(16):1156–
1162. [PubMed: 11036121] 
9. Rovin BH, et al. Efficacy and safety of rituximab in patients with active proliferative lupus 
nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012; 64(4):
1215–1226. [PubMed: 22231479] 
10. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev 
Immunol. 1996; 14:233–258. [PubMed: 8717514] 
11. Bahlis NJ, et al. CD28-mediated regulation of multiple myeloma cell proliferation and survival. 
Blood. 2007; 109(11):5002–5010. [PubMed: 17311991] 
12. Nair JR, et al. CD28 expressed on malignant plasma cells induces a prosurvival and 
immunosuppressive microenvironment. J Immunol. 2011; 187(3):1243–1253. [PubMed: 
21715687] 
13. Njau MN, et al. CD28-B7 interaction modulates short- and long-lived plasma cell function. J 
Immunol. 2012; 189(6):2758–2767. [PubMed: 22908331] 
14. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and 
cyclophosphamide. J Immunol. 2001; 166(5):2913–2916. [PubMed: 11207238] 
15. Schiffer L, et al. Short term administration of costimulatory blockade and cyclophosphamide 
induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism 
downstream of renal immune complex deposition. J Immunol. 2003; 171(1):489–497. [PubMed: 
12817034] 
16. Genovese MC, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha 
inhibition. N Engl J Med. 2005; 353(11):1114–1123. [PubMed: 16162882] 
17. Kremer JM, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid 
arthritis: a randomized trial. Ann Intern Med. 2006; 144(12):865–876. [PubMed: 16785475] 
18. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of 
complete response support conflicting conclusions. Arthritis Rheum. 2012; 64(11):3660–3665. 
[PubMed: 22806274] 
19. Yu CC, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013; 369(25):
2416–2423. [PubMed: 24206430] 
20. McHorney CA, et al. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data 
quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994; 32(1):
40–66. [PubMed: 8277801] 
et al. Page 9









21. Hay EM, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease 
activity in systemic lupus erythematosus. Q J Med. 1993; 86(7):447–458. [PubMed: 8210301] 
22. Dai Z, Lakkis FG. The role of cytokines, CTLA-4 and costimulation in transplant tolerance and 
rejection. Curr Opin Immunol. 1999; 11(5):504–508. [PubMed: 10508707] 
23. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994; 
265(5176):1225–1227. [PubMed: 7520604] 
24. Illei GG, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone 
improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann 
Intern Med. 2001; 135(4):248–257. [PubMed: 11511139] 
25. Mok CC, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment 
for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 2004; 50(8):2559–2568. 
[PubMed: 15334470] 
26. Moroni G, et al. What happens after complete withdrawal of therapy in patients with lupus 
nephritis. Clin Exp Rheumatol. 2013; 31(Suppl. 78):S57–S81.
27. McCarty DJ, et al. Incidence of systemic lupus erythematosus. Race and gender differences. 
Arthritis Rheum. 1995; 38(9):1260–1270. [PubMed: 7575721] 
28. Fernandez M, et al. A multiethnic, multicenter cohort of patients with systemic lupus 
erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum. 2007; 
57(4):576–584. [PubMed: 17471524] 
29. Pons-Estel GJ, Alarcon GS. Lupus in Hispanics: a matter of serious concern. Cleve Clin J Med. 
2012; 79(12):824–834. [PubMed: 23208987] 
30. Richman IB, et al. European genetic ancestry is associated with a decreased risk of lupus nephritis. 
Arthritis Rheum. 2012; 64(10):3374–3382. [PubMed: 23023776] 
31. Gonzalez LA, et al. Ethnicity in systemic lupus erythematosus (SLE): its influence on 
susceptibility and outcomes. Lupus. 2013; 22(12):1214–1224. [PubMed: 24097993] 
32. Feldman CH, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and 
lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013; 
65(3):753–763. [PubMed: 23203603] 
et al. Page 10










Treatment assignments and withdrawals in the intention-to-treat population.
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Complete response rate (A) and total response rate (complete responses plus partial 
responses) (B) at week 24 among control subjects treated with either the Euro-Lupus (EL) 
regimen or the EL regimen plus abatacpet (EL+ABA).
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Table 1






Age (years) – mean±SD 32.7 ± 12.0 32.0 ± 10.1
Females 64 (94%) 58 (88%)
Primary Race
  White 33 (49%) 34 (51%)
  Black 25 (37%) 27 (41%)
  Asian 3 (4%) 3 (5%)
  Mixed or Undeclared 7 (10%) 2 (3%)
Ethnicity
  Hispanic/Mestizo 28 (41%) 25 (38%)
Weight (kg) 75 ± 23 74 ± 18
Blood pressure (mm Hg)
  Systolic 133 ± 17 130 ±17
  Diastolic 83 ± 11 79 ± 12
Time from onset of lupus nephritis
  <1 year 48 (71%) 47 (71%)
ISN/RPS** classification
  Class III 11 10
  Class IV 24 24
    Segmental 8 10
    Global 16 14
  Class III + V 12 12
  Class IV + V 20 20
Renal function
  Serum creatinine (mg/dl) 1.3 ± 0.6 1.2 ± 0.7
  Estimated GFR (ml/min/1.73 m2) 58 ± 28 65 ± 36
Urine protein
  24-hour total (gm/d) 4.5 ± 4.0 3.8 ± 3.1
  Protein:creatinine ratio (mg/mg) 4.1 ± 3.4 3.6 ± 2.6
  UPCR >3 31 (46%) 27 (41%)
Serum albumin (g/dl) 2.7 ± 0.7 2.8 ±0.6
Serology (at randomization)
  ANA positive (≥1:80) 68 (100%) 66 (100%)
  Anti-dsDNA positive 50 (75%) 49 (75%)
  C3 complement low 44 (70%) 47 (78%)
  C4 complement low 37 (59%) 39 (65%)
Patient global assessment 45 ± 28 42 ±30
SF-36
  Physical component score 39 ± 10 39 ± 11















  Mental component score 40 ± 13 40 ± 13
*
Except where noted, values are the number (%). Percentages are calculated out of the number of subjects with evaluable data.
**
ISN/RPS – International Society of Nephrology/Renal Pathology Society. Biopsies were read and classified by pathologists at the local sites.
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Table 2
Secondary outcome measures at week 24*
Outcome measure Control Abatacept
Urinary protein-to-creatinine ratio, mean ± SD 1.1 ± 1.2 1.1 ± 1.3
Disappearance of anti-dsDNA antibody 4/36 (11) 9/38 (24)
Correction of low C3 concentration 11/30 (37) 14/38 (37)
Correction of low C4 concentration 10/25 (40) 17/32 (53)
Total BILAG score, mean ± SD 3.4 ± 1.8 3.8 ± 3.0
Patient’s global assessment, mean ± SD 28 ± 25 18 ± 22
SF-36, mean ± SD
  Physical component score 45.3 ± 11 45.3 ± 11
  Mental component score 46.5 ± 11 45.9 ± 12
Subjects with lupus flares
  Renal flare 3/68 (4.4) 3/66 (4.5)
  Nonrenal flare 6/68 (9) 8/66 (12)
Complete response by race/ethnicity
  Race
    White 14/33 (42) 12/34 (35)
    African American 4/25 (16) 9/27 (33)
    Asian 1/3 (33) 1/3 (33)
    Mixed or undeclared 2/7 (29) 0/2 (0)
  Ethnicity
    Hispanic/Mestizo 10/28 (36) 8/25 (32)
    Not Hispanic/Mestizo 11/40 (28) 14/41 (34)
Total response by race/ethnicity†
  Race
    White 21/33 (64) 22/34 (65)
    African American 14/25 (56) 15/27 (56)
    Asian 2/3 (67) 1/3 (33)
    Mixed race or undeclared 3/7 (43) 1/2 (50)
  Ethnicity
    Hispanic/Mestizo 16/28 (57) 15/25 (60)
    Not Hispanic/Mestizo 24/40 (60) 24/41 (59)
*
Except where indicated otherwise, values are the number of patients/number evaluated (%). Values for urinary protein-to-creatinine ratio were 
compared using a 2-sided t-test from an analysis of covariance (ANCOVA) model on log(urinary protein-to-creatinine ratio) that was adjusted for 
log(baseline values). Values for disappearance of anti—double-stranded DNA (anti-dsDNA) antibody and lupus flares were compared using a 2-
sided Pearson’s chi-square test. Values for total British Isles Lupus Assessment Group (BILAG) score were compared using a 2-sided t-test from 
an analysis of variance model. Values for patient’s global assessment and Short Form 36 (SF-36) were compared using actual values between 
experimental and control groups and a 2-sided t-test from an ANCOVA model that adjusts for baseline values. None of the differences were 
statistically significant.
†
Total response included patients in whom a complete response or a partial response was achieved.
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Table 3





Any AE 56 (82) 56 (85)
Infection-related AEs 32 (47) 31(47)
Grade 3 or higher AEs 24 (35) 21(32)
Infection-related grade 3 or higher AEs 5 (7) 8 (12)
Serious AEs 20 (29) 19 (28)
Deaths 1 0
AEs resulting in withdrawal from study 17 (25) 11(16)
*Values are the number (%). AE = adverse event.
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Table 4
Outcome at week 52*
Control Abatacept
Patients with a complete response at week 24
  No. of patients 21 22
  Status at week 52
    Complete response, no. (%) 13 (62) 11 (50)
    Partial response 1 1
    Loss of renal response† 4 2
    Withdrew (nonrenal SLE flare) 0 1
    Withdrew (unrelated to SLE or abatacept) 3 7
Patients with a partial response at week 24
  No. of patients 19 17
  Status at week 52
    Complete response, no. (%) 9(47) 7(41)
    Partial response 4 6
    Loss of renal response† 5 1
    Withdrew (nonrenal SLE flare) 0 0
    Withdrew (unrelated to SLE or abatacept) 1 3
Total response at week 52, no./no. evaluated (%)‡ 27/40(68) 25/39(64)
*
Except where indicated otherwise, values are the number of patients. SLE = systemic lupus erythematosus.
†
Either withdrew due to renal flare or did not meet complete response or partial response criteria at week 52.
‡
Total response included patients in whom a complete response was achieved and patients in whom a partial response was achieved.
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